<?xml version='1.0' encoding='utf-8'?>
<document id="28265691"><sentence text="Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants." /><sentence text="BMS-986142 is an oral, small-molecule reversible inhibitor of Bruton's tyrosine kinase"><entity charOffset="71-79" id="DDI-PubMed.28265691.s2.e0" text="tyrosine" /></sentence><sentence text=" The main objectives of our phase I studies were to characterize the safety and tolerability, pharmacokinetics, and pharmacodynamics of BMS-986142 in healthy participants, and to investigate the potential for the effect of BMS-986142 on the PK of methotrexate (MTX) in combination"><entity charOffset="247-259" id="DDI-PubMed.28265691.s3.e0" text="methotrexate" /><entity charOffset="261-264" id="DDI-PubMed.28265691.s3.e1" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28265691.s3.e0" e2="DDI-PubMed.28265691.s3.e0" /><pair ddi="false" e1="DDI-PubMed.28265691.s3.e0" e2="DDI-PubMed.28265691.s3.e1" /></sentence><sentence text="" /><sentence text="In a combined single ascending dose and multiple ascending dose study, the safety, pharmacokinetics, and pharmacodynamics of BMS-986142 were assessed in healthy non-Japanese participants following administration of a single dose (5-900 mg) or multiple doses (25-350 mg, once daily for 14 days)" /><sentence text=" In a drug-drug interaction study, the effect of BMS-986142 (350 mg, once daily for 5 days) on the single-dose pharmacokinetics of MTX (7"><entity charOffset="131-134" id="DDI-PubMed.28265691.s6.e0" text="MTX" /></sentence><sentence text="5 mg) was assessed in healthy participants" /><sentence text="" /><sentence text="BMS-986142 was generally well tolerated, alone and in combination with MTX"><entity charOffset="71-73" id="DDI-PubMed.28265691.s9.e0" text="MTX" /></sentence><sentence text=" BMS-986142 was rapidly absorbed with peak concentrations occurring within 2 h, and was eliminated with a mean half-life ranging from 7 to 11 h" /><sentence text=" Exposure of BMS-986142 appeared dose proportional within the dose ranges tested" /><sentence text=" A dose- and concentration-dependent inhibition of CD69 expression was observed following administration of BMS-986142"><entity charOffset="108-118" id="DDI-PubMed.28265691.s12.e0" text="BMS-986142" /></sentence><sentence text=" BMS-986142 did not affect the pharmacokinetics of MTX"><entity charOffset="51-60" id="DDI-PubMed.28265691.s13.e0" text="MTX" /></sentence><sentence text="" /><sentence text="BMS-986142 was well tolerated at the doses tested, had pharmacokinetic and pharmacodynamic profiles which support once-daily dosing, and can be coadministered with MTX without the pharmacokinetic interaction of BMS-986142 on MTX"><entity charOffset="0-10" id="DDI-PubMed.28265691.s15.e0" text="BMS-986142" /><entity charOffset="164-173" id="DDI-PubMed.28265691.s15.e1" text="MTX" /><entity charOffset="225-234" id="DDI-PubMed.28265691.s15.e2" text="MTX" /><pair ddi="false" e1="DDI-PubMed.28265691.s15.e0" e2="DDI-PubMed.28265691.s15.e0" /><pair ddi="false" e1="DDI-PubMed.28265691.s15.e0" e2="DDI-PubMed.28265691.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28265691.s15.e0" e2="DDI-PubMed.28265691.s15.e2" /><pair ddi="false" e1="DDI-PubMed.28265691.s15.e1" e2="DDI-PubMed.28265691.s15.e1" /><pair ddi="false" e1="DDI-PubMed.28265691.s15.e1" e2="DDI-PubMed.28265691.s15.e2" /></sentence><sentence text="" /></document>